Why CurQfen® is mentioned as new generation bioavailable curcumin – beyond the ‘number of folds’? What is FCR?

The current understanding on curcumin pharmacokinetics and pharmacodynamics urge for non-NANO & natural delivery forms (regulatory compliance) capable of providing FREE curcuminoids over conjugated metabolites and proof for the same. It has to be noted that even unformulated curcumin has been shown to provide free curcuminoids into plasma and absorbs via lymphatic system, though majority of absorption is via blood. In 2008, Begum et al detected and estimated curcuminoids in rat plasma and brain tissues at significantly high levels when chronically fed with 2000 ppm curcumin, indicating that ‘unformulated curcumin’ can provide free curcuminoids in plasma, further to brain tissues and can lead to amyloid-plaque reduction ( J Pharmacol Exptl Ther, 2008, 321, 196-208) . But, once it is metabolised to conjugates (glucuronides/sulfates), all these properties are getting lost. So, a new generation bioavailable curcumin should talk about the ratio of plasma concentration of free curcuminoids to conjugated curcuminoids (FCR), more than the number of folds of bioavailability. FCR will reflect how much curcuminoids are absorbed in free form and how much in conjugated form. Higher the FCR, better the formulation (JFF 2016).

CurQfen® is the only formulation which has determined FCR of 1.3. Once free curcuminoids are available in the systemic circulation, it gets automatically absorbed into brain and other tissues. So, brain tissue distribution is a litmus test for free curcuminoids bioavailability. CurQfen® has addressed and proved all these check points and published in peer reviewed journals (JFF 2015, 2016). It is 100% Natural, food-grade, CLEAN label and free from excipients.